Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues0000000000000000000000000000
% growth66 %47 %54 %20 %20 %21 %22 %
EBITDA0000000000000000000000000000
% EBITDA margin(129 %)(117 %)(121 %)(79 %)(51 %)(37 %)(3 %)
Profit0000000000000000000000000000
% profit margin(155 %)(115 %)(107 %)(83 %)(62 %)(45 %)(25 %)
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue48 %52 %59 %44 %---
  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor

$0.0

round
investor investor

$0.0

round
investor investor investor investor

$0.0

round
N/A

$0.0

round
N/A

$0.0

Valuation: $0.0

34.6x EV/LTM Revenues

-7.0x EV/LTM EBITDA

round
N/A

$0.0

round
*
N/A

$250m

Post IPO Equity
Total Funding000k

Recent News about Twist Bioscience

Edit
More about Twist Bioscienceinfo icon
Edit

Twist Bioscience is a pioneering company in the field of DNA synthesis, based in San Francisco. The company specializes in creating synthetic DNA, which is crucial for various applications in biotechnology, pharmaceuticals, and research. Twist Bioscience serves a diverse range of clients, including academic institutions, pharmaceutical companies, and biotechnology firms. These clients use Twist's products for purposes such as developing new drugs, diagnosing diseases, and conducting genetic research.

The market Twist Bioscience operates in is the synthetic biology and genomics sector, which is rapidly growing due to advancements in technology and increasing demand for personalized medicine. The company stands out by offering high-quality DNA sequences at competitive prices, which has been a significant draw for its user community.

Twist Bioscience's business model revolves around the production and sale of synthetic DNA. They have developed a proprietary platform that allows them to produce DNA sequences quickly and accurately. This platform uses a smart algorithm to determine if a DNA sequence can be synthesized, providing instant feedback to customers. The company offers a range of products, including genes, oligo pools (short DNA sequences), variant libraries (collections of DNA sequences with slight variations), and tools for SARS-CoV-2 (the virus causing COVID-19). They also provide DNA data storage solutions and next-generation sequencing (NGS) services.

Twist Bioscience makes money by selling these DNA products and services to its clients. They have positioned themselves as a next-generation supplier, capable of rapidly providing thousands of genes, which has been highly anticipated by the scientific community. Their ability to handle complex DNA sequences that are difficult to work with has made them a valuable partner for many research projects.

In summary, Twist Bioscience is a leading innovator in DNA synthesis, serving a wide range of clients in the biotech and pharmaceutical industries. They operate in the synthetic biology market, offering high-quality DNA products and services, and generate revenue through sales of these products.

Keywords: DNA synthesis, biotechnology, pharmaceuticals, genomics, synthetic biology, gene sequencing, COVID-19 tools, DNA storage, NGS services, research.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Twist Bioscience

Edit
Genome Compiler
ACQUISITION by Twist Bioscience Apr 2016
iGenomX
ACQUISITION by Twist Bioscience Jun 2021
Abveris Antibody
ACQUISITION by Twist Bioscience Nov 2021